• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Ad hoc announcements pursuant to Art. 53 LR
  • PolyPeptide signs significant commercial agreement

PolyPeptide signs significant commercial agreement

19 December 2022
Ad hoc announcements pursuant to Art. 53 LR

Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial agreement for one of its phase III custom projects.   

As reported with half-year results on 19 August 2022, the custom projects pipeline of PolyPeptide included 218 active projects at the end of June 2022, of which 30 were in phase III of clinical development.

For one of these projects, PolyPeptide has now reached a milestone by signing a multi-year commercial agreement with an annual order value of around EUR 100 million after a ramp-up phase starting in 2024. The agreement is subject to the usual customer confidentiality. It is consistent with the mid-term outlook communicated by PolyPeptide on 19 August 2022 and provides for additional order value potential over time.

This milestone is the result of a successful project collaboration over several years between PolyPeptide and its customer, with whom it maintains a long-standing relationship. For production, PolyPeptide will utilize the new large-scale solid phase synthesis infrastructure that it plans to bring online in Braine-l’Alleud (Belgium) in early 2024. The facility will be deploying advanced technology, resulting in a high degree of automation and productivity.

Raymond De Vré, Chief Executive Officer of PolyPeptide, commented:

“The signing of the agreement reinforces our confidence in the growth opportunities in our market and, more specifically, within our pipeline of phase III custom projects. We are proud to contribute day-by-day to the development and supply of drugs to the benefit of millions of patients.”

[…]

Download PDF (English)

Download PDF (German)

Back to news

Related posts

11 March 2025

PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth


Read more
13 August 2024

Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028


Read more
12 March 2024

PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers